MEDP

Medpace Holdings, Inc.

$622.43

+0.45% 2026-10-20

Health CareS&P 400

1M 3M 6M 1Y 2Y

MEDPSPY

+2.1%

+1.6%

+17.1%

+20.9%

YTD

+10.8%

+14.3%

Live chart

Loading live chart…

Grades vs sector

Momentum

39th pct in sector

C-

12-1 return: +6.7%
Percentile within its GICS sector across the S&P 1500.

Growth

76th pct in sector

B+

Revenue growth (YoY): +17.2%
Percentile within its GICS sector across the S&P 1500.

Value

15th pct in sector

D-

Forward E/P: 3.1% · EBITDA/EV: 3.6%
Percentile within its GICS sector across the S&P 1500.

Profitability

88th pct in sector

Profit margin: +17.7% · Return on equity: +162.2%
Percentile within its GICS sector across the S&P 1500.

Revisions

Not enough data yet

–

EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Our models

Not held by any of our 5 live models right now.

Quality Growth

not ranked (outside this model's universe or screens)

Momentum Top 15

not ranked (outside this model's universe or screens)

Momentum Blend

not in the current book

New Highs Growth

rank 66 of 589 · 12-1 momentum % 18.6

Conviction 20

not in the current book

News

More news

What To Expect From Medpace’s (MEDP) Q3 Earnings

StockStory · 19h ago

Don’t Chase Medpace Stock Here Despite Its Strong Technical Momentum

Barchart · Oct 15

CON vs. MEDP: Which Stock Should Value Investors Buy Now?

Zacks · Oct 14

Medpace (MEDP) Dips More Than Broader Market: What You Should Know

Zacks · Oct 13

Medpace (MEDP) Stock Declines While Market Improves: Some Information for Investors

Zacks · Oct 06

Key stats

Market cap$17.4B

P/E (trailing)36.5

P/E (forward)32.2

52-week range373.00 – 677.90

Revenue growth (YoY, latest qtr)+17.2%

Dividend yield0.00%

Analyst consensusHold (13)

Mean price target$595.92 (-4%)

Valuation and fundamentals

Valuation & fundamentals

Bottom line

Leans undervalued

Model read-out from the numbers below, not advice. Score +2 (DCF counts double).

▲DCF (base case)above the price by 33%

▼Forward P/E vs sector32.2x vs median 17.6x

▲Piotroski F-score7/9

▲Altman Z8.1 (safe)

▲Net debt / EBITDA-0.9x

•Analyst target-4% (13 analysts)

Discounted cash flow

Bear

$477

-23%

growth 11% · disc. 11.2% · term. 2.0%

Base

$829

+33%

growth 19% · disc. 10.2% · term. 2.5%

Bull

$1,314

+111%

growth 23% · disc. 9.2% · term. 3.0%

A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.

Reverse DCFfor context, not a signal

Today's price assumes free cash flow grows about 10% a year for 10 years.

Implied

+10%/yr

FCF, last 3 yrs

+25%/yr

FCF, last 5 yrs

+25%/yr

Revenue, last 3 yrs

+20%/yr

Revenue, last 5 yrs

+22%/yr

Same inputs as the DCF above: trailing free cash flow 0.7B, 10.2% discount rate, 2.5% growth after year 10, net cash and today's share count. Actual growth rates are compound annual rates from SEC annual filings through FY2025; "n/a" means too little history or a negative starting year.

Edit assumptions · recalculates instantly

Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.18 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs Health Care

P/E (trailing)

sector median 29.9× · 63rd pct

36.5×
pricier

Forward P/E

sector median 17.6× · 87th pct

32.2×
pricier

EV / EBITDA

sector median 15.8× · 85th pct

28.9×
pricier

Price / sales

sector median 3.1× · 73rd pct

6.2×
pricier

Price / book

sector median 3.5× · 98th pct

40.0×
pricier

FCF yield

sector median 4.1% · 50th pct

4.1%
pricier

Forward EPS $19.32 vs trailing $17.03 (+13% expected growth). Forward P/E uses analysts' next-12-month estimate.

Backlog (remaining performance obligations)

RPO

$3.5B

as of 2026-06-30

vs a year ago

+0%

YoY

× TTM revenue

1.26×

coverage

24-09

24-12

25-03

25-06

25-09

25-12

26-03

26-06

Contracted revenue not yet recognized, from SEC filings (XBRL tag RevenueRemainingPerformanceObligation).

Quality & financial health

Gross margin

–

Operating margin

21.0%

FCF margin

25.4%

Net margin

17.7%

Return on equity

113.3%

Return on invested capital

–

Net debt / EBITDA

-0.9×

Current ratio

0.7×

Interest cover

–

Cash conversion (OCF/NI)

1.5×

Piotroski F-score 7/9 · last two fiscal years

✓ Positive net income✓ Positive operating cash flow✓ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✗ Current ratio improved✓ No share dilution✗ Gross margin improved✓ Asset turnover improved

Altman Z-score 8.1 (safe zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.

Analysts

Mean target

$596

-4%

Analysts

Hold

Range

$370–$700

low – high

● price · ◆ mean target

Annual history

FY	Revenue	Net income	Free cash flow
2025	$2.5B	$451.1M	$681.9M
2024	$2.1B	$404.4M	$572.3M
2023	$1.9B	$282.8M	$396.7M
2022	$1.5B	$245.4M	$351.2M
2021	$1.1B	$181.8M	$235.1M
2020	$925.9M	$145.4M	$227.3M

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +20.1%.

Earnings

Next report: 2026-10-21 · after close · EPS est 4.46

EstimateActual (beat)Actual (miss)

Report	EPS est	Actual	Surprise
2026-07-22	4.00	4.25	+6.2%
2026-04-22	3.96	4.28	+8.2%
2026-02-09	4.23	4.67	+10.5%
2025-10-22	3.57	3.86	+8.1%
2025-07-21	3.00	3.10	+3.5%
2025-04-21	3.07	3.67	+19.6%
2025-02-10	3.12	3.68	+18.1%
2024-10-21	2.87	3.01	+5.2%

Quarterly revenue

Quarter	Revenue	YoY
2026-06-30	$707.3M	+17.2%
2026-03-31	$706.6M	–
2025-12-31	$708.5M	–
2025-09-30	$659.9M	–
2025-06-30	$603.3M	–

Analyst actions

Mizuho

2026-10-07 · main

Outperform → Outperform
PT $700

Barclays

2026-10-07 · main

Equal-Weight → Equal-Weight
PT $625

UBS

2026-09-30 · up

Sell → Neutral
PT $673

Mizuho

2026-07-24 · main

Outperform → Outperform
PT $665

BMO Capital

2026-07-24 · main

Market Perform → Market Perform
PT $600

Truist Securities

2026-07-24 · main

Hold → Hold
PT $609

Insider trades

Troendle August J.

Director, President & CEO, 10% owner · 2026-09-30

SELL
$13.7M

Troendle August J.

Director, President & CEO, 10% owner · 2026-09-29

SELL
$16.6M

Troendle August J.

Director, President & CEO, 10% owner · 2026-09-28

SELL
$1.5M

Troendle August J.

Director, President & CEO, 10% owner · 2026-09-25

SELL
$95.6K

Troendle August J.

Director, President & CEO, 10% owner · 2026-09-24

SELL
$17.3M

Troendle August J.

Director, President & CEO, 10% owner · 2026-09-23

SELL
$10.1M

Troendle August J.

Director, President & CEO, 10% owner · 2026-09-22

SELL
$30.8M

Troendle August J.

Director, President & CEO, 10% owner · 2026-09-21

SELL
$13.6M

Troendle August J.

Director, President & CEO, 10% owner · 2026-09-17

SELL
$6.7M

Troendle August J.

Director, President & CEO, 10% owner · 2026-09-16

SELL
$5.4M

Troendle August J.

Director, President & CEO, 10% owner · 2026-09-15

SELL
$9.9M

Troendle August J.

Director, President & CEO, 10% owner · 2026-08-27

SELL
$403.2K

Stats refreshed 2026-10-20 18:02:42 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

coteau

Coteau Systematic Strategies publishes stock research and model portfolios. It doesn't manage money or give investment advice. Results are hypothetical unless marked Live. Data: Yahoo Finance (delayed) and SEC EDGAR.

How it works Disclaimer Terms Privacy Data status